Inspire And Kirin Enter Diagnostics Collaboration

Inspire Pharmaceuticals, Inc. announced a licensing agreement with Kirin Brewery Co., Ltd., of Tokyo, Japan, in which Kirin’s Pharmaceutical Division has obtained rights to develop and commercialise Inspire’s lung-disease diagnostic adjunct product, INS316 Diagnostic, in twenty- one Asian countries and regions including Japan. The initial indication for INS316 will be to aid in the diagnosis Read more about Inspire And Kirin Enter Diagnostics Collaboration[…]

Entelos Evaluates Potential Asthma Treatments For Bayer

Entelos, Inc. has announced the completion of a professional services engagement with Bayer AG, to evaluate an IL-4 receptor antagonist as a potential treatment for asthmatics. Entelos applied their predictive asthma PhysioLab technology to Bayer’s proprietary animal model data in order to assess the impact of treatment on a variety of patient types and to Read more about Entelos Evaluates Potential Asthma Treatments For Bayer[…]

Skyepharma Plans Joint Development With Novartis

SkyePharma PLC announced an agreement with Novartis Pharma AG to jointly develop a new product for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The product will combine Novartis’ novel long-acting bronchodilator QAB149 with two SkyePharma technologies SkyeHaler(TM), a breath-activated multi-dose dry powder inhaler (MDDPI) device, to be marketed by Novartis as the Read more about Skyepharma Plans Joint Development With Novartis[…]

Discovery And Aerogen Collaborate

Discovery Laboratories, Inc. and Aerogen, Inc. have entered into a collaborative relationship to evaluate the use of Discovery’s proprietary humanized lung surfactant with Aerogen’s Aeroneb Professional Nebulizer System (Aeroneb Pro), for the delivery of aerosolized surfactants to prevent and treat respiratory disease in the hospital. Aerogen’s commercially available Aeroneb Pro is a new nebulizer designed Read more about Discovery And Aerogen Collaborate[…]

Clenbuterol – Designed For Asthma Patients

Clenbuterol is not an only drug that has been used for some other purpose instead of the relevant use for which it is designed. However, there are several other pain killer medicines that are used as for addiction and as a substitute of drugs. Asthma patients use mouth spray at the time of breathing attack. Read more about Clenbuterol – Designed For Asthma Patients[…]

Discovery And Collagenex Collaborate

Discovery Laboratories, Inc. and CollaGenex Pharmaceuticals, Inc. announced a research collaboration to evaluate the combination of their platform technologies for the development of novel respiratory disease therapeutics. The two companies will collaborate on the preclinical evaluation of an aerosolized formulation of Discovery’s humanized lung surfactants combined with CollaGenex‘s IMPACS (Inhibitors of Multiple Proteases and CytokineS) Read more about Discovery And Collagenex Collaborate[…]

Arriva Signs Agreement For Respiratory Disease Treatment

Arriva Pharmaceuticals, Inc. has signed an agreement to develop and commercialise the synthetic matrix metalloprotease inhibitor (MMPI) Ilomastat for the treatment of inflammatory respiratory diseases. “This is a further demonstration of our strategy, which aims to build a product pipeline in protease inhibitors and respiratory diseases,” said Martin Preuveneers, Ph.D., Chairman and CEO of Arriva. Read more about Arriva Signs Agreement For Respiratory Disease Treatment[…]